ReviR Therapeutics Secures $4.6M CIRM Grant for Dual-Target Huntington's Disease Therapy
核心洞察
ReviR Therapeutics (搜索) received a $4.6 million grant from the California Institute for Regenerative Medicine (搜索) to advance its HTT-PMS1 (搜索) genetic medicine program for Huntington's disease (搜索) treatment.
The company's novel dual-mechanism approach targets both mutant huntingtin protein (搜索) and PMS1 (搜索) enzyme to reduce toxic protein aggregates and curtail somatic CAG repeat expansion in HD patients.
ReviR has identified a lead compound that meets key development criteria and plans to advance the orally administered small molecule therapy through preclinical studies toward clinical trials.
ReviR Therapeutics (搜索) announced it has secured a $4.6 million grant from the California Institute for Regenerative Medicine (搜索) (CIRM) to advance its innovative dual-target approach for treating Huntington's disease (搜索). The Brisbane, California-based biotech company also revealed it has reached a key development milestone by identifying a lead compound that meets critical development criteria for its HTT-PMS1 (搜索) genetic medicine program.
The CIRM grant, awarded through a competitive peer-review process, will support the development of a transformative therapy that employs a dual-mechanism approach to combat Huntington's disease (搜索) by targeting both mutant huntingtin protein (搜索) (mHTT) and the protein mismatch repair enzyme PMS1 (搜索). This novel therapeutic strategy selectively reduces the mRNA of two genes implicated in both the cause and progression of HD.
Dual-Mechanism Therapeutic Approach
ReviR's innovative therapy addresses two critical drivers of Huntington's pathology simultaneously. By selectively degrading the mRNA of these key targets, the treatment not only reduces the toxic protein aggregates associated with the disease but also curtails the somatic CAG repeat expansion in HD patients, potentially altering the long-term course of the disease.
The company's proprietary VoyageR technology platform enables this dual-targeting approach through a small molecule that can be administered orally, representing a significant advancement in accessibility for HD patients. This oral delivery method would mark a breakthrough in enhancing patient compliance and quality of life compared to existing treatment options.
Understanding Huntington's Disease Pathology
Huntington's disease (搜索) is a neurodegenerative disorder caused by an abnormal expansion of CAG trinucleotide repeats in the huntingtin (搜索) (HTT) gene. Individuals with HD have more than 36 CAG repeats in the HTT gene, resulting in the production of mutant huntingtin protein (搜索) with an expanded polyglutamine tract. This aberrant protein undergoes misfolding and aggregation within neurons, disrupting various cellular functions.
Recent research has revealed that while the CAG length is fixed at birth, the repeats can further expand over time within certain brain cells. Once these expansions exceed a critical threshold of approximately 150 CAG repeats, they cause neuronal death, leading to the development of HD symptoms.
Clinical Development Plans
The CIRM funding will enable ReviR Therapeutics (搜索) to advance their preclinical candidate through rigorous preclinical studies and into clinical trials. The initial goal is to ensure that the therapy is both effective in reducing disease progression and amenable to routine clinical use.
"This CIRM grant is a cornerstone for our targeted approach in treating Huntington's disease (搜索)," said Paul R. August, PhD, Chief Scientific Officer at ReviR Therapeutics (搜索). "By leveraging our proprietary RNA-targeting technology and our platform VoyageR, this molecule is poised to revolutionize how we treat HD - offering not just symptomatic relief but a potential disease-modifying therapy, filling an unmet medical need."
Company Pipeline and Vision
ReviR Therapeutics (搜索), founded in 2021 by leaders in computational biology, RNA biology, and drug discovery, focuses on developing innovative therapies for patients with serious neurogenetic diseases. The company's lead candidate, RTX-117 (搜索), is an investigational small molecule therapy for neurogenetic diseases including Charcot-Marie-Tooth disease (搜索) (CMT). The pipeline includes other orally administered small molecules designed to modulate RNA function.
"We are grateful to CIRM for validating our scientific approach and funding the development of this life-changing therapy for HD patients and other neurodegenerative diseases," said Peng Yue, PhD, co-founder and CEO of ReviR Therapeutics (搜索). "This grant will help us advance our dual HTT-PMS1 (搜索) program toward clinical trials, potentially transforming the treatment landscape for Huntington's disease (搜索) patients."
The development of this therapeutic asset is expected to pave the way for similar therapies targeting other genetic disorders, representing a potential paradigm shift in the treatment of neurodegenerative diseases through more accessible treatment options.